Valuation: ABVC BioPharma, Inc.

Market Cap 38.66M 33.85M 31.25M 29.18M 54.94M 3.66B 56.19M 376M 145M 1.8B 145M 142M 6.26B P/E 2024
-1.4x
P/E 2025 -5.42x
Enterprise Value 41.39M 36.24M 33.46M 31.24M 58.81M 3.91B 60.15M 403M 155M 1.93B 155M 152M 6.7B EV / Sales 2024
19.8x
EV / Sales 2025 -
Free-Float
79.2%
Yield 2024 *
-
Yield 2025 -
1 day+2.61%
1 week+18.94%
Current month+11.35%
1 month+11.35%
3 months+72.64%
6 months-32.03%
Current year-26.29%
1 week 1.28
Extreme 1.28
1.61
1 month 1.19
Extreme 1.19
1.61
Current year 0.88
Extreme 0.8801
2.43
1 year 0.88
Extreme 0.8801
5.48
3 years 0.4
Extreme 0.4
6.87
5 years 0.4
Extreme 0.4
116.9
10 years 0.4
Extreme 0.4
378
Manager TitleAgeSince
Chief Executive Officer 40 2023-06-22
Chief Executive Officer 39 2015-06-30
Chief Tech/Sci/R&D Officer 72 2023-06-12
Director TitleAgeSince
Chairman 39 2015-06-30
Director/Board Member 65 2017-11-22
Director/Board Member 55 2017-11-22
Date Insider Type Main position Quantity % Market Cap.
22-05-19Other

Chairman

7,908,805 26.0954%
21-08-01Other

Chief Executive Officer

18,404 0.0752%
21-08-01Other

Director

6,067 0.0248%
Change 5-day change 1-year change 3-year change Capi.($)
+2.61%+18.94%-29.44%-68.73% 38.66M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+4.51%-11.47%-11.91% 23.07B
+1.32%+6.22%+4.07%+415.45% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+5.71%+23.15%+186.29% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.37%+7.49%+40.42%+114.27% 22.63B
Weighted average by Cap. +3.33%+7.62%+53.98%+128.49%

Financials

2024 2025
Net sales 510K 446K 412K 385K 724K 48.18M 741K 4.96M 1.91M 23.77M 1.91M 1.87M 82.52M -
Net income -4.9M -4.29M -3.96M -3.7M -6.97M -464M -7.13M -47.69M -18.41M -229M -18.41M -18.01M -794M -7.91M -6.92M -6.39M -5.97M -11.24M -748M -11.49M -76.93M -29.7M -369M -29.7M -29.05M -1.28B
Net Debt 2.88M 2.52M 2.33M 2.18M 4.1M 272M 4.19M 28.03M 10.82M 134M 10.82M 10.59M 467M 2.73M 2.39M 2.2M 2.06M 3.88M 258M 3.96M 26.53M 10.24M 127M 10.24M 10.02M 442M
Logo ABVC BioPharma, Inc.
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.
Employees
18
Date Price Change Volume
26-06-29 US$1.570 +2.61% 183,345
26-06-26 US$1.530 +5.52% 216,682
26-06-25 US$1.450 +9.02% 354,399
26-06-24 US$1.330 +1.53% 73,338
26-06-23 US$1.310 -0.76% 94,576
  1. Stock Market
  2. Stocks
  3. ABVC Stock